In preclinical models, CXB significantly inhibited tumor proliferation in head and neck squamous cell carcinoma (Yip-Schneider et al. 2001), and in OSCC cells in-vitro (Shin et al. 2013). CXB inhibited FOXM1, a transcription factor that controls OSCC development and promotes angiogenesis, invasion, and metastasis (Lam et al. 2013). A 5-week CXB treatment significantly reduced OSCC tumor growth in a murine xenograft model, reversing EMT progression biomarkers like Snail suppression and cadherin switch initiation (Yang et al. 2006). Here, CDH17 is linked to head and neck squamous cell carcinoma.